Toripalimab (Anti-PDCD1 / PD-1 / CD279)

Toripalimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody targeting PD-1. It has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. 147.3 KD.